Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
BioPorto Diagnostics and QIAGEN have successfully validated the use of BioPorto’s gRAD lateral flow platform on QIAGENS’s ESEQuant LR3 Lateral Flow System.
By combining gRAD with the ESEQuant LRS system, this platform, provides a powerful and versatile toolbox for rapid development of lateral flow-based assays. This toolbox is well suited in the constantly shifting lateral flow market space, where the demand for new applications in human diagnostics, veterinary diagnostics, food industry and environmental/agriculture testing is rapidly increasing.
Jan Kuhlmann Andersen, COO of BioPorto, commented: “With the gRAD platform BioPorto Diagnostics has the ability to offer assay developers across several industries contract development of their assay development. Through the combination of gRAD and the ESEQuant LRS system, BioPorto now has a complete assay development process in place to test across above mentioned business segments.”
Read more about the gRAD lateral flow technology and the ESEQuant LR3 Lateral Flow technology.
www.bioporto.com/Products/Product-by-category/Lateral-flow.aspx
http://www.lateralflowreader.com/new-powerful-option-esequant-lr3-grad/
For further information, please contact:
Peter Mørch Eriksen, CEO
Gry Husby Larsen, General Counsel
Telephone +45 4529 0000, e-mail [email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/3275dac8-8136-4c84-a74d-b229acccc5eb
